Logo

JSR Life Sciences Launches Similis Bio Business Division to Accelerate Biosimilar Development

Share this

JSR Life Sciences Launches Similis Bio Business Division to Accelerate Biosimilar Development

Shots:

  • The company launched its new business division, Similis Bio to improve efficiency & costs for biosimilar development by using the combined experience & technical knowledge of leaders in analytical, cell-line & process development
  • Similis will supply companies & offers analytical & process development data to determine an appropriate biosimilar target, accelerate early program development & reduce analytical costs
  • Similis Bio will foster co-development agreements with companies to develop biosimilar programs in which partners will get an exclusive right to purchase multiple programs. JSR designed Similis’ collaboration model is intended to reduce the risks of canceled programs and extend market analysis timelines

Ref: Businesswire | Image: JSR Life Sciences

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions